Skip to content
Clinical Trials – home
FinlandBack to Finland

Clinical trials in Turku – page 2

300 clinical trials in Turku, Finland across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FinlandOur site in FinlandKliinisetTutkimukset.fi(opens in a new tab)
Turku at a glance
300
clinical trials
  • Research sites5
Type of trial
Recruitment status
Quick filters

300 trials in Turku

Open in trial search

Influenza+1

Recruiting

Efficacy and safety of the investigational mRNA influenza vaccine gskvx000000077430 (drug combination) in adults ≥ 65 years

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:65+ years · Healthy volunteers
  • Substances:INFLUENZA A VIRUS, A/CROATIA/10136RV/2023 (H3N2) LIKE STRAIN X-425A, INACTIVATED
  • Sponsor:GlaxoSmithKline Biologicals

Rinatabart Sesutecan with or without bevacizumab versus standard platinum‑based chemotherapy drug combination in patients with recurrent platinum‑sensitive ovarian cancer

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib Mesilate
  • Sponsor:Glaxosmithkline Research & Development Limited

Safety of PF-07872412 versus 20‑valent pneumococcal conjugate vaccine in healthy infants for prevention of pneumococcal disease

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years
  • Substances:PF-07831695
  • Sponsor:Pfizer Inc.

A double‑blind, placebo‑controlled trial of oral BI 1015550 in patients with systemic sclerosis

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:BI 1015550
  • Sponsor:Boehringer Ingelheim Espana S.A.

A Phase III Study of Elafibranor in Adults with Primary Sclerosing Cholangitis to Assess Efficacy and Safety

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Elafibranor
  • Sponsor:Ipsen Bioscience Inc.

Efficacy and safety of votoplam in adults with Huntington’s disease: a randomized, double‑blind, placebo‑controlled Phase 3 trial

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Votoplam
  • Sponsor:Novartis Pharma AG

Osteosarcoma

Recruiting

Cabozantinib Maintenance Therapy vs Best Supportive Care in Osteosarcoma Patients in Complete Remission or with Residual Disease after First‑Line Chemotherapy

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Institut Gustave Roussy

Efficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Rinatabart Sesutecan plus bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Incyte Corp.

Safety and Tolerability of Oral SUN-627 in Adults with Non‑Active Progressive Multiple Sclerosis (SPMS/PPMS) – Phase 2a Study

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years

Other cities in Finland

The busiest research cities in the country

All 28 cities in Finland

Clinical research in Turku

What the registry says about research in the country

01 Respiratory Diseases

Comprehensive research focusing on respiratory infections including trials for influenza, RSV, and human metapneumovirus vaccines. Studies evaluate preventive measures for vulnerable populations.

  • Influenza vaccine development
  • RSV prevention in adults and infants
  • Viral respiratory infections

Multiple trials aim to enhance protection against seasonal respiratory illnesses in different age groups.

02 Infectious Diseases

Research centered on preventing and treating various infectious conditions, including studies of meningococcal vaccines and innovative approaches to viral infections.

  • Meningococcal prevention
  • Herpes Zoster vaccination
  • Yellow fever immunity

Studies focus on developing effective vaccination strategies for different age groups and populations.

03 Metabolic Disorders

Innovative trials examining treatments for obesity and diabetes, with particular attention to weight management therapies and metabolic health improvements.

  • Weight management interventions
  • Type 2 diabetes treatments
  • Combined therapeutic approaches

Research emphasizes lifestyle modifications alongside medical interventions.

04 Oncology

Advanced research in cancer treatment, particularly focusing on breast cancer and innovative therapeutic combinations for improved patient outcomes.

  • Breast cancer therapies
  • Leukemia treatments
  • Prostate cancer interventions

Studies evaluate both targeted therapies and combination treatments.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.